Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.75
Bid: 2.60
Ask: 2.90
Change: 0.00 (0.00%)
Spread: 0.30 (11.538%)
Open: 2.75
High: 2.75
Low: 2.75
Prev. Close: 2.75
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Good Energy says ZapMap expands into mainland Europe

Wed, 13th Dec 2023 21:14

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

British Smaller Cos VCT PLC and VCT 2 - Leeds, England-based venture capital trusts - Confirm the addition of an over-allotment facility of GBP25 million to their subscription offer, following its launch in September. Add that they have received applications approaching GBP60 million so far, with the deadline for applications on March 28, 2024. Notes subscription was initially launched to raise GBP65 million.

----------

Frontier IP Group PLC - London-based intellectual property commercialisation company - Says portfolio company The Vaccine Group has appointed three animal health experts to its advisory board in order to support the scale-up of its herpesvirus-based platform. Says advisory board members are Merck & Co Inc's Christophe Barnier-Quer, as well as Johan Dreesen and Vaughn Kubiak. Neil Crabb, Frontier IP Chief Executive Officer, says: "I am delighted TVG has been able to form an advisory group of such good quality. It is a testament to the potential of the Company, its vaccine platform and pipeline, and I look forward to further developments as TVG's vaccines move towards scale up and full commercialisation."

----------

DeepVerge PLC - Dublin-based environmental and life sciences firm - Says it has made progress in its discussions with potential buyers of assets and intellectual property in its Modern Water and Labskin business units. Adds that it hopes to agree on a sale in January. Says, however, that even if both asset sets are sold, the sales will not be of enough value to avoid closure or administration of the two subsidiaries. Adds that it currently has debts of GBP300,000 and is unsure whether it will have the funds to pay these debts. Says shares expected to be cancelled on December 27.

----------

Good Energy Group PLC - Wiltshire, England-based supplier of 100% renewable power and an innovator in energy services - Says investee company Zapmap, an electric vehicle charge point mapping service, has expanded its market presence to mainland Europe. Says its mapping service is now available in France, Germany, Belgium, the Netherlands and Luxembourg. Says coming months will see Zapmap open features including EV route planning and charging payments. Good Energy Chief Executive Nigel Pocklington says: "Zapmap has made significant progress over the last year as it continues to broaden and deepen its market presence in the UK and now across Europe. It continues to track with the rapidly growing electric vehicle market, which has expanded by 40% in the UK last year with the share of electric vehicles new car registrations increasing in almost all EU countries."

----------

ValiRx PLC - life science company based near Birmingham, England, which is focused on early-stage cancer therapeutics and women's health - Launches placing to raise GBP1.6 million, via the issue of 26.3 million shares at 6.0 pence each. Adds that it will also launch a retail offer at 6.0 pence per retail share. Says retail offer is only open to existing shareholders. Notes that certain directors will also subscribe for 500,000 shares at 6.0p each. Says it will raise GBP1.9 million in total, which will be used to integrate BioBank materials form its asset acquisition from Imagen, as well as research and development.

----------

Creo Medical Group PLC - Chepstow, Wales-based medical device company - Says it has completed the first procedure using Speedboat Ultraslim. Says the product was used for a lower Gastrointestinal tract procedure in the UK, with the first European procedure expected to follow shortly. Speedboat is used to treat gastrointestinal tract diseases, including bowel, stomach and oesophagus cancers. CEO Craig Gulliford comments: "This is yet another landmark moment for Creo Medical. We know what a difference this even smaller device will make in terms of broadening access to advanced energy in endoscopy for a wider pool of clinicians. Speedboat UltraSlim is compatible with all major endoscopes, meaning clinicians can bring advanced energy to their practices, allowing more patients to be treated endoscopically, which avoids surgery and the associated secondary costs and risks."

----------

Macfarlane Group PLC - Glasgow-based supplier of packaging materials - Promotes James Baird to senior independent director.

----------

Asia Strategic Holdings Ltd - Singapore-based developer and operator of consumer businesses located in emerging Asian economies - Agrees amended loan facility with Macan Pte Ltd, increasing its loan to USD4.5 million, from USD3.0 million. Adds that the increase is in order to support its expansion of its school network. Notes that it has agreed to extend the repayment date to December 31 2027. Macan is the largest shareholder of Asia Strategic, representing 32.4%, while Asia Strategic Chief Executive Enrico Cesenni holds 35.1% of the voting rights of Macan.

----------

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
24 Jun 2014 09:23

DIRECTOR DEALINGS: ValiRx Directors Buy 5.3 Million Shares

Read more
10 Jun 2014 10:00

ValiRx Submits Application For VAL201 Cancer Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that it has submitted an application to the Medicines and Healthcare Products Regulatory Agency for a phase I/II extended clinical study, or trial, of VAL201 in people with cancer. VAL201 is ValiRx's leading anti-cancer therapeutic candidate.

Read more
10 Jun 2014 09:45

Tuesday broker round-up UPDATE

ASOS: Goldman Sachs reduces target price from 6250p to 5750p, while upgrading to strong buy. Avon Rubber: Investec lowers target price from 690p to 680p and downgrades from buy to add. BAE Systems: Investec downgrades from add to hold with a target price of 430p. BG Group: Exane downgrades to neu

Read more
15 May 2014 13:31

ValiRx Sees Progress On Cancer Drug Development From Joint Venture

LONDON (Alliance News) - ValiRx PLC said Thursday that it had seen promising progress on the development of its cancer treatment VAL401 towards Phase II trials since the formation of its joint venture with Tangent Reprofiling Ltd, ValiSeek. The joint venture was formed a month ago to progre

Read more
1 May 2014 10:15

ValiRx Granted Patent For Cancer Screening Biomarker In Japan

LONDON (Alliance News) - ValiRx PLC said Thursday that it had been granted a patent in Japan for its cancer screening test gene biomarker NAV3. The biomarker was acquired by the company's subsidiary ValiFinn Oy in 2012. As a result, ValiRx now has patent protection on this biomarker i

Read more
8 Apr 2014 11:05

ValirX In Joint Venture With Tangent Reprofiling For Cancer Drug Development

LONDON (Alliance News) - ValiRx PLC Tuesday said it has established a risk-sharing joint venture with Tangent Reprofiling Ltd which will progress Tangent's VAL401 potential cancer drug through its remaining preclinical development and towards Phase II trials. ValirX said it has acquired a 6

Read more
1 Apr 2014 09:22

ValiRx Anti-Cancer Compound To Undergo Further Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that its clinical trial project team for its anti-cancer compound VAL201 has recommended a further stability and sterility study to allow for the acceleration towards a Phase 2 efficacy study. ValiRx said it had accepted the advice of the tea

Read more
19 Mar 2014 12:10

ValiRx Loss Widens As It Ups Investment In Clinical Trial Programme

LONDON (Alliance News) - Biotechnology company ValiRx PLC Wednesday posted a widened pretax loss in 2013 as revenue declined, and it upped investment in the clinical trial programme for its anti-cancer therapeutic VAL201. The company posted a pretax loss of GBP2.9 million, widened from GBP2

Read more
20 Feb 2014 11:10

ValiRx Biomarket Receives European Patent Approval

LONDON (Alliance News) - ValiRx PLC Thursday said a cancer screening test gene biomarker called NAV3, acquired by its subsidiary in 2012, has received patent approval from the European Patent Office. In a statement, ValiRx said the latest approval means it has biomarker patent protection in

Read more
31 Jan 2014 13:03

ValiRx Sells Shares In VolitionRx For USD601,578

LONDON (Alliance News) - ValirRx PLC Friday said it has sold its shareholding in VolitionRx to an unnamed firm for USD601,578 and will use the proceeds for the continuing clinical development of its anti-cancer therapeutics VAL101 and VAL201. The life science company had 510,811 shares in c

Read more
27 Dec 2013 08:27

ValiRx Raises GBP2.9 Million In Placing To Fund Oncology Work

Read more
28 Nov 2013 12:27

CORRECT: AIM IN BRIEF: Herstal Emerges As Favourite To Acquire Manroy

Read more
28 Nov 2013 08:22

AIM IN BRIEF: Beretta Emerges As Favourite To Acquire Manroy

Read more
15 Nov 2013 12:39

CORRECT: ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

Read more
15 Nov 2013 12:37

UK WINNERS & LOSERS: IAG Dives Despite Raising Profit Guidance

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.